This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $27.07 in the latest trading session, marking a -0.48% move from the prior day.
Is Trending Stock Teladoc Health, Inc. (TDOC) a Buy Now?
by Zacks Equity Research
Teladoc (TDOC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $27.20, marking a -1.66% move from the previous day.
Teladoc (TDOC) to Reduce Operating Costs, Shares Fall 6.6%
by Zacks Equity Research
Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.
2 Former Pandemic Darlings Poised to Lead Again
by Andrew Rocco
Easy money, stimulus, and a new generation of investors led to the rise and fall of many pandemic darlings. In today's article, Andrew Rocco investigates two that may have turnaround potential.
Teladoc Health, Inc. (TDOC) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Teladoc (TDOC). This makes it worthwhile to examine what the stock has in store.
Teladoc (TDOC) Boosts Revenue Guidance, Shares Jump 4.1%
by Zacks Equity Research
Teladoc (TDOC) expects around $1 billion in revenues from its BetterHelp mental health business in 2022.
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $22.29, moving -0.71% from the previous trading session.
Teladoc (TDOC) Unveils App to Simplify Whole-Person Care
by Zacks Equity Research
Teladoc Health (TDOC) launches a digital app that will provide a broad range of TDOC's services to cater to the whole-person health needs of members.
Teladoc (TDOC) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Teladoc (TDOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pandemic Winners Turned Losers: Worth Another Look?
by Derek Lewis
In 2022, these once seemingly unstoppable investments have plunged into the red, undoubtedly impacting many portfolios.
Teladoc (TDOC) Achieves Momentous 50M Milestone in Visits
by Zacks Equity Research
Of the 50 million visits to Teladoc (TDOC), around one-third took place in the last year alone.
Teladoc (TDOC) Up 1.6% Since Q3 Earnings Beat on Higher Visits
by Zacks Equity Research
Teladoc (TDOC) projects total visits in the band of 18.4-18.6 million for 2022.
Wall Street Analysts Believe Teladoc (TDOC) Could Rally 54%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 53.6% upside potential for Teladoc (TDOC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Teladoc Health, Inc. (TDOC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Teladoc (TDOC). This makes it worthwhile to examine what the stock has in store.
Teladoc (TDOC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 23.73% and 0.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Must See Earnings Charts This Week
by Tracey Ryniec
Can you trust in the big cap growth companies in 2022? These 5 companies will set the tone.
3 Healthcare Stocks Set to Outshine Q3 Earnings Estimates
by Kaibalya Pravo Dey
Recovering volumes, improved admissions, growing health awareness and wide utilization of technologies in the third quarter are expected to have aided healthcare stocks like Humana (HUM), Teladoc (TDOC) and Pediatrix Medical (MD).
Can Rising Visits Help Teladoc (TDOC) Beat on Earnings in Q3?
by Zacks Equity Research
The third-quarter results of Teladoc (TDOC) are likely to reflect a rise in Access Fees and Visit Fee revenues.
Teladoc (TDOC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $24.03 in the latest trading session, marking a +0.46% move from the prior day.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $23.92, moving -1.36% from the previous trading session.
Pediatrix Medical Group (MD) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pediatrix Medical Group (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Teladoc (TDOC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health (ELV) to Post Q3 Earnings: A Beat in the Cards?
by Zacks Equity Research
Elevance Health's (ELV) third-quarter results are likely to reflect improved premiums and net investment income.
Teladoc (TDOC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $25.03 in the latest trading session, marking a +1.3% move from the prior day.